Exploring Stakeholders' Perspectives on Implementing Universal Germline Testing for Colorectal Cancer: Findings From a Clinical Practice Survey
Linda Rodgers(Massachusetts General Hospital), Rachel Hodan(Stanford Health Care), Mev Dominguez–Valentin(Norwegian Cancer Society), José G. Guillem(Memorial Sloan Kettering Cancer Center), Bryson W. Katona(Washington University in St. Louis), Francesc Balaguer(Universitat de Barcelona), Eduardo Vilar(The University of Texas MD Anderson Cancer Center), Charité Ricker(University of Southern California), Joshua Melson(Rush University Medical Center), Maheen Farooqi(University of Southern California), Brian H. Shirts(University of Washington), David Liska(Cleveland Clinic), Sanjeevani Arora(Fox Chase Cancer Center), Kathryn A. Mraz, Dan Li(Kaiser Permanente Santa Clara Medical Center), Priyanka Kanth(University of Utah)
Cited by 3
Related Papers
Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer
|JAMA Oncology|2016|721
Practice Parameters for the Management of Rectal Cancer (Revised)
|Diseases of the Colon & Rectum|2013|565
Outcome of Primary Tumor in Patients With Synchronous Stage IV Colorectal Cancer Receiving Combination Chemotherapy Without Surgery As Initial Treatment
|Journal of Clinical Oncology|2009|390